Abstract:Renal denervation (RDN) has emerged as a novel therapy for drug-resistant hypertension. We here examined the effects of RDN at early versus advanced stages of hypertension on blood pressure and organ pathology in rats with salt-sensitive hypertension. Dahl salt-sensitive (DahlS) rats fed an 8% NaCl diet from 6 weeks of age were subjected to RDN (surgical ablation and application of 10% phenol in ethanol) or sham surgery at 7 (early stage) or 9 (advanced stage) weeks and were studied at 12 weeks. RDN at early or advanced stages resulted in a moderate lowering of blood pressure. Although RDN at neither stage affected left ventricular (LV) and cardiomyocyte hypertrophy, it ameliorated LV diastolic dysfunction, fibrosis, and inflammation at both stages. Intervention at both stages also attenuated renal injury as well as downregulated the expression of angiotensinogen and angiotensin-converting enzyme (ACE) genes and angiotensin II type 1 receptor protein in the kidney. Furthermore, RDN at both stages inhibited proinflammatory gene expression in adipose tissue. The early intervention reduced both visceral fat mass and adipocyte size in association with downregulation of angiotensinogen and ACE gene expression. In contrast, the late intervention increased fat mass without affecting adipocyte size as well as attenuated angiotensinogen and ACE gene expression. Our results thus indicate that RDN at early or late stages after salt loading moderately alleviated hypertension and substantially ameliorated cardiac and renal injury and adipose tissue inflammation in DahlS rats. They also suggest that cross talk among the kidney, cardiovascular system, and adipose tissue may contribute to salt-sensitive hypertension.

What problem does this paper attempt to address?

This paper aims to explore the effects of renal denervation (RDN) on blood pressure and the pathology of the heart, kidney, and adipose tissue in the early or late stages of hypertension. Specifically, the researchers used salt - sensitive Dahl salt - sensitive rats (DahlS rats). These rats started on an 8% high - salt diet at 6 weeks of age and underwent RDN surgery or sham surgery at 7 weeks (early) or 9 weeks (late), and finally, various indicators were evaluated at 12 weeks. ### Research Background - **Hypertension**: Hypertension is one of the leading causes of premature death worldwide, but its underlying mechanisms are not yet fully understood. The renal sympathetic nerve is considered a major contributor in the pathophysiology of hypertension. - **Renal Denervation (RDN)**: RDN is a treatment method to reduce blood pressure by reducing renal sympathetic nerve activity and has shown effectiveness in drug - resistant hypertension in clinical trials. ### Research Objectives - **Evaluate the Effects of RDN**: To study the effects of RDN on blood pressure, heart, kidney, and adipose tissue pathological changes in the early and late stages of hypertension. - **Explore the Mechanisms**: To explore how RDN affects the renin - angiotensin system (RAS), inflammatory response, and tissue damage, and how these changes are associated with the development of hypertension. ### Main Findings - **Blood Pressure Reduction**: Whether RDN is performed in the early or late stage of hypertension, it can moderately reduce blood pressure. - **Cardioprotection**: RDN can improve left ventricular diastolic dysfunction, fibrosis, and inflammation in both stages, but has no significant effect on cardiomyocyte hypertrophy. - **Renal Protection**: RDN can reduce kidney damage in both stages and down - regulate the expression of RAS - related genes (such as angiotensinogen and angiotensin - converting enzyme genes) in renal tissue. - **Adipose Tissue Inflammation**: RDN can inhibit the expression of pro - inflammatory genes in adipose tissue in both stages. Early intervention can also reduce visceral fat mass and adipocyte size, while late intervention increases fat mass but does not affect adipocyte size. - **Effects on the Circulatory System**: RDN does not affect the levels of circulating inflammatory cytokines or the excretion of norepinephrine in urine in both stages. However, late - stage RDN significantly reduces plasma renin activity and angiotensin II concentration. ### Conclusions - **Efficacy of RDN**: RDN can moderately reduce blood pressure in both the early and late stages of hypertension and significantly improve the pathological damage of the heart and kidney and the inflammation of adipose tissue. - **Mechanism Exploration**: The research results suggest that the interaction between the kidney, cardiovascular system, and adipose tissue may play an important role in the development of salt - sensitive hypertension. ### Significance - **Clinical Application Prospects**: RDN may have therapeutic potential for patients with salt - sensitive hypertension, especially when the intervention is early. - **Future Research Directions**: Future research can further explore the application effects of RDN in different types of hypertensive patients, as well as its long - term safety and effectiveness.

Comparison of the effects of renal denervation at early or advanced stages of hypertension on cardiac, renal, and adipose tissue pathology in Dahl salt-sensitive rats

Renal Denervation Significantly Attenuates Cardiorenal Fibrosis in Rats with Sustained Pressure Overload.

Beneficial effects of renal denervation on cardiac angiogenesis in rats with prolonged pressure overload.

The effects of renal denervation on blood pressure, cardiac hypertrophy, and sympathetic activity during the established phase of hypertension in spontaneously hypertensive rats

Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy

Renal denervation alters ambulatory blood pressure-derived salt sensitivity index in patients with uncontrolled hypertension

Renal denervation: a key approach to hypertension and cardiovascular disease

Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction

Catheter-Based Renal Denervation Attenuates Kidney Interstitial Fibrosis in a Canine Model of High-Fat Diet-Induced Hypertension

Renal Denervation Attenuates Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice Independent of Blood Pressure Lowering

Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome

Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials

Effects of renal denervation on the incidence and severity of cardiovascular diseases

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Afferent Renal Denervation Attenuates Sympathetic Overactivation From the Paraventricular Nucleus in Spontaneously Hypertensive Rats

Renal denervation for hypertensive heart disease and atrial fibrillation

Renal denervation improves mitochondrial oxidative stress and cardiac hypertrophy through inactivating SP1/BACH1-PACS2 signaling

Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 transgenic hypertensive rats with volume overload induced using aorto-caval fistula

Abstract 15000: Renal Denervation Improves Cardiac Function and Mitigates Pathophysiological Changes in a Novel Murine Model of Heart Failure With Preserved Ejection Fraction

Effects of bilateral renal denervation on open-loop baroreflex function and urine excretion in spontaneously hypertensive rats

Dietary Effects on Dahl Salt-Sensitive Hypertension, Renal Damage, and the T Lymphocyte Transcriptome.